Skip to main content
Clinical Trials/NCT02533193
NCT02533193
Completed
N/A

A Randomized Controlled Trial of Enhanced Recovery After Surgery Protocal Versus Traditional Care in Laparoscopic Hepatectomy

Sir Run Run Shaw Hospital1 site in 1 country126 target enrollmentAugust 2015
ConditionsLiver Diseases

Overview

Phase
N/A
Intervention
Not specified
Conditions
Liver Diseases
Sponsor
Sir Run Run Shaw Hospital
Enrollment
126
Locations
1
Primary Endpoint
Recovering Rate
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The purpose of this study is to investigate the clinical value of enhanced recovery after surgery protocal in laparoscopic hepatectomy by assessing its outcomes and hospital stay days comparing with traditional care .

Detailed Description

The ERAS programs has been proved to be a useful solutions in patients undergoing colorectal surgery in terms of significantly reduced postoperative complications and shorter length of hospital stay, compared to the patients of conventional treatment. But few studies reported about the ERAS programs in the laparoscopic hepatectomy. The purpose of this study is to investigate the clinical value of enhanced recovery after surgery protocal in laparoscopic hepatectomy by assessing its outcomes and hospital stay days comparing with traditional care .

Registry
clinicaltrials.gov
Start Date
August 2015
End Date
August 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Xiujun Cai

President

Sir Run Run Shaw Hospital

Eligibility Criteria

Inclusion Criteria

  • If patients were diagnosed with tumors
  • Located at segment Ⅱ、Ⅲ、Ⅳb、Ⅴ or Ⅵ
  • The tumor location and size do not affect the dissection of hepatic hilar region
  • Tumor size less than 10cm
  • Without portal vein tumor thrombus
  • Without intrahepatic or distant metastasis
  • Partial resection or half liver resection
  • Willingness to participate in the study
  • Able to understand the nature of the study and what will be required of them
  • Body mass index of between 18 and 35

Exclusion Criteria

  • Pregnant or lactating women
  • Unwillingness to participate
  • Inability to give written informed consent
  • Child-Pugh classification of C
  • ASA grading of IV to V
  • Tumor invasion of the inferior vena cava or confluence part of hepatic vein
  • Decompensated liver cirrhosis

Outcomes

Primary Outcomes

Recovering Rate

Time Frame: 6 days after surgery

1. No major complication 2. Tolerance of semiliquid diet 3. Normal activity 4. Good pain control with analgesic-free or oral analgesics.

post-operative hospital stay

Time Frame: up to 4 weeks after surgery

participants will be followed for the duration of hospital stay, an expected average of 6 days

Secondary Outcomes

  • cost of hospitalization(up to 1 month after surgery)
  • associated cytokines in peripheral blood (IL-6, IL-10 and TNF-α)(before the operation, on postoperation 1 day, postoperation 2 day, postoperation 4 day)
  • Estimated blood loss(the day of surgery)
  • Time to functional recovery (days from operation to functional recovery)(up to 4 weeks after surgery)
  • Quality of life(up to 1 month after surgery)
  • Visual Analog Score for pain(up to 5 days after surgery)
  • liver function(up to 1 month after surgery)
  • operation time(the day of surgery)

Study Sites (1)

Loading locations...

Similar Trials